Yeast-based vaccine provides rationale for human cancer studies Scientists have found that vaccination with a heat-killed, nontoxic yeast that is genetically engineered to manufacture a common tumor protein can induce specific and repeated anti-tumor immune responses in mice.Vaccination extends...
Early CEA feasible after minor stroke MedWire News: Carotid endarterectomy (CEA) performed in neurologically stable patients within 2 weeks of a minor stroke is a relatively low-risk procedure, study results suggest.'There is compelling evidence...
that CEA is...
Yeast-based vaccine induces immune responses and reduces tumor size in mice Medical Research News Scientists have found that vaccination with a heat-killed, non-toxic yeast that is genetically engineered to manufacture a common tumor protein can induce specific and repeated anti-tumor immune responses in mice.
Yeast-Based Vaccine Induces Immune Responses and Reduces Tumor Size in Mice Scientists have found that vaccination with a heat-killed, nontoxic yeast that is genetically engineered to manufacture a common tumor protein can induce specific and repeated anti-tumor immune responses in mice.Vaccination extends...
Yeast-Based Vaccine Induces Immune Responses and Reduces Tumor Size in Mice Scientists have found that vaccination with a heat-killed, non-toxic yeast that is genetically engineered to manufacture a common tumor protein can induce specific and repeated anti-tumor immune responses in mice.Vaccination extends...
Personalizing Medicine: New Research Shows Potential Of Targeted Therapies For Cancer A new study, presented at the SNM 55th Annual Meeting, shows the potential to pre-target the treatment of cancer cells--bringing personalized medicine one step closer from the laboratory to patients.By combining new molecular imaging...
Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmun Partners Expect Program to Advance to the Clinic Within a Year; Studies Generate Milestone Payment to Micromet BETHESDA, Md., and ZURICH, Switzerland, June 24 /PRNewswire/ -- Micromet, Inc.and Nycomed today announced the initiation of...
::: Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoi Partners Expect Program to Advance to the Clinic Within a Year; Studies Generate Milestone Payment to Micromet Bethesda, MD and Zurich, Switzerland - June 24, 2008 - Micromet, Inc.(Nasdaq: MITI) and Nycomed today announced the initiation...
Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmun BETHESDA, Md., and ZURICH, Switzerland, June 24 /PRNewswire/ -- Micromet, Inc.(Nasdaq: MITI) and Nycomed today announced the initiation of formal preclinical safety studies for the anti-GM-CSF human antibody MT203.
Micromet received ...
Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmun BETHESDA, Md., and ZURICH, Switzerland, June 24 /PRNewswire/ -- Micromet, Inc.(Nasdaq: MITI) and Nycomed today announced the initiation of formal preclinical safety studies for the anti-GM-CSF human antibody MT203.
Micromet received ...
Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmun BETHESDA, Md., and ZURICH, Switzerland, June 24 /PRNewswire/ -- Micromet, Inc.(Nasdaq: MITI) and Nycomed today announced the initiation of formal preclinical safety studies for the anti-GM-CSF human antibody MT203.
Micromet received ...
Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmun BETHESDA, Md., and ZURICH, Switzerland, June 24 /PRNewswire/ -- Micromet, Inc.(Nasdaq: MITI) and Nycomed today announced the initiation of formal preclinical safety studies for the anti-GM-CSF human antibody MT203.
Micromet received ...
Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmun BETHESDA, Md., and ZURICH, Switzerland, June 24 /PRNewswire/ -- Micromet, Inc.(Nasdaq: MITI) and Nycomed today announced the initiation of formal preclinical safety studies for the anti-GM-CSF human antibody MT203.
Micromet received ...
Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmun BETHESDA, Md., and ZURICH, Switzerland, June 24 /PRNewswire/ -- Micromet, Inc.(Nasdaq: MITI) and Nycomed today announced the initiation of formal preclinical safety studies for the anti-GM-CSF human antibody MT203.
Micromet received ...
Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmun BETHESDA, Md., and ZURICH, Switzerland, June 24 /PRNewswire/ -- Micromet, Inc.(Nasdaq: MITI) and Nycomed today announced the initiation of formal preclinical safety studies for the anti-GM-CSF human antibody MT203.
Micromet received ...
Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmun BETHESDA, Md., and ZURICH, Switzerland, June 24 /PRNewswire/ -- Micromet, Inc.(Nasdaq: MITI) and Nycomed today announced the initiation of formal preclinical safety studies for the anti-GM-CSF human antibody MT203.
Micromet received ...
Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmun BETHESDA, Md., and ZURICH, Switzerland, June 24 /PRNewswire/ -- Micromet, Inc.(Nasdaq: MITI) and Nycomed today announced the initiation of formal preclinical safety studies for the anti-GM-CSF human antibody MT203.
Micromet received ...
Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmun Partners Expect Program to Advance to the Clinic Within a Year; Studies Generate Milestone Payment to Micromet BETHESDA, Md., and ZURICH, Switzerland, June 24 /PRNewswire/ -- Micromet, Inc.(Nasdaq: MITI - News) and Nycomed today announced...
Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody BETHESDA, Md., and ZURICH, Switzerland, June 24 /PRNewswire/ -- Micromet, (News) Inc.and Nycomed today announced the initiation of formal preclinical safety studies for the anti-GM-CSF human antibody MT203.
Micromet received $775,000 ...
Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmun BETHESDA, Md., and ZURICH, Switzerland, June 24 /PRNewswire/ -- Micromet, Inc.(Nasdaq: MITI) and Nycomed today announced the initiation of formal preclinical safety studies for the anti-GM-CSF human antibody MT203.
Micromet received ...
An Interview With Kenneth Rosenfield, MD An expert asserts the importance of trials and registries, reflecting on lessons learned from his own experience, and discusses this year's VIVA meeting.What are the key components to achieving 'global vascular' management of peripheral...
Personalized cancer therapy one step closer to reality Washington, June 17 : Combining new molecular imaging techniques with targeted therapy may give cancer patients a more individualized treatment that can increase the effectiveness of therapies and minimize treatment discomfort.In...
Personalized cancer therapy one step closer to reality Combining new molecular imaging techniques with targeted therapy may give cancer patients a more individualized treatment that can increase the effectiveness of therapies and minimize treatment discomfort.In traditional radioimmunoimaging...
Personalizing medicine: New research shows potential of targeted therapies for cancer Pre-targeting strategies could lead to individualized cancer therapies, say researchers at SNM's 55th Annual Meeting NEW ORLEANS, La.A new study, presented at the SNM 55th Annual Meeting, shows the potential to pre-target the treatment of...
Immunomedics' Pretargeting Method May Improve Radioimmunoimaging of Cancer (PRIME NEWSWIRE) -- Immunomedics, Inc.(NasdaqGM:IMMU - News), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that pretargeting with a bispecific antibody ...
